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Abstract
Background: Most epidemiological and clinical reports on snake envenoming focus on a single country and describe rural
communities as being at greatest risk. Reports linking snakebite vulnerability to socioeconomic status are usually limited to
anecdotal statements. The few reports with a global perspective have identified the tropical regions of Asia and Africa as
suffering the highest levels of snakebite-induced mortality. Our analysis examined the association between globally
available data on snakebite-induced mortality and socioeconomic indicators of poverty.
Methodology/Principal Findings: We acquired data on (i) the Human Development Index, (ii) the Per Capita Government
Expenditure on Health, (iii) the Percentage Labour Force in Agriculture and (iv) Gross Domestic Product Per Capita from
publicly available databases on the 138 countries for which snakebite-induced mortality rates have recently been estimated.
The socioeconomic datasets were then plotted against the snakebite-induced mortality estimates (where both datasets
were available) and the relationship determined. Each analysis illustrated a strong association between snakebite-induced
mortality and poverty.
Conclusions/Significance: This study, the first of its kind, unequivocally demonstrates that snake envenoming is a disease of
the poor. The negative association between snakebite deaths and government expenditure on health confirms that the
burden of mortality is highest in those countries least able to deal with the considerable financial cost of snakebite.
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Introduction
Our knowledge of the global medical burden of snakebite is
limited to just a few reports based primarily on either hospital
records [1] or the epidemiological literature [2,3], and more
recently, the latter in combination with WHO mortality data
[4]. Despite the nearly universal distribution of venomous
snakes (the South Pole, Greenland, New Zealand and Mada-
gascar being the major exceptions), each report concludes that
the medical importance of snakebite is greatest in the tropics.
The vast majority of snakebite-induced deaths (Figure 1) occur
in Asia (estimates ranging from 15,400–57,600 deaths pa) and
sub-saharan Africa (3,500–32,100 deaths pa) [4]. Populations in
this geographic zone also suffer the medical burden of the
world’s neglected tropical diseases (NTD). Importantly, the
number of snakebite-induced deaths doubles the NTD mortality
figures for this region due to African trypanosomiasis, cholera,
dengue haemorrhagic fever, leishmaniasis, Japanese encephalitis
and schistosomiasis [5–7]. A major distinctive characteristic
of the NTDs is that they are globally associated with poverty
[8]. In line with the recent WHO categorisation of snake
envenoming as a NTD [9], this analysis was therefore
conducted to determine whether the medical burden of snake
envenoming is, like the other NTDs, also associated with
poverty.
Methodology
To gain a global perspective of the relationship between poverty
and lethal snake envenoming, we entered the now readily available
country-specific snakebite mortality data [Supplement 2, [4]] into
Epi-Info (version3.5.1) software package [http://www.cdc.gov/
epiinfo] to populate the global map of snakebite mortality by
country (Figure 1); this differs slightly from the map presented in
the report by Kasturiratne et al [4] which presented the same data
by geographic region. Entering this country-specific, rather than
regional, data provided us with a sufficient spread of data to have
confidence in the statistical validity of plotting the mortality data
against appropriate socioeconomic indicators. This analysis was
performed on the understanding that national estimates of
snakebite mortality were not likely to be as accurate as that for
the reported wider regions [4], since many of the country estimates
were necessarily (because of the lack of available data) extrapo-
lations from neighbouring countries. From amongst the large
variety of socioeconomic data available in the public domain, we
acquired country-by-country data for ‘Gross Domestic Product
Per Capita, US$’ and ‘The Percentage of the Labour Force in
Agriculture’ from the CIA World Factbook database [https://
www.cia.gov/library/publications/the-world-factbook/]. The da-
ta on ‘Per Capita Government Expenditure on Health, US$’ was
taken from the World Health Organisation Statistical Information
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System (WHOSIS) database [http://apps.who.int/whosis/data/
Search.jsp]. These three datasets were selected because of the
potential link between snakebite mortality and an individual’s
high-risk agricultural occupation, income and access to healthcare.
The Human Development Index (HDI; a composite indicator that
reflects life expectancy, education and literacy and standard of
living measured by GDP) was also examined and countries
categorised into Low (0.1 to 0.499), Medium (0.500 to 0.799) or
High (above 0.800) HDI status.
Results
Statistically linear relationships were found between the
logarithm of snakebite mortality and the HDI (Figure 2a), the
logarithm of Per Capita Government Expenditure on Health (2b),
the Percentage of the Labour Force in Agriculture (2c) and the
logarithm of GDP Per Capita (2d). The strength of each of these
relationships was determined using the Pearson correlation
coefficient; all four correlations were numerically strong (range:
r = 0.571–0.651) and statistically highly significant (p,0.001).
Discussion
The World Bank defined the absolute poverty line as the
percentage of a country’s population living on an income of less
than US$2 per day [10]. Maps depicting countries based on this
definition of poverty [11] show a remarkably similar profile as the
snakebite mortality map (Figure 1). This relationship between
poverty and snakebite mortality is clearly demonstrated by the
strong negative correlation between snakebite mortality and both
HDI and GDP/capita reported here (Figure 2). The literature on
snake envenoming is, like global poverty, rich with references
associating rural agriculture with high incidence of disease and
death. Taking West Africa as a detailed example, farmers and
children in rural communities are consistently identified as being
the highest snakebite risk groups in Senegal [12], the Gambia [13],
Mali [14], Cote D-Ivoire [15], Ghana [16], Benin [17], Niger
[18], Nigeria [19–21], Cameroon [22], Gabon [23] and the
Congo [24]. The numerous epidemiological reports conducted in
Asia and Latin America similarly emphasise that rural subsistent
farming communities in these regions also suffer snakebite as a
daily occupational hazard (Figure 3). It is not surprising therefore
Figure 1. Annual snakebite mortality. Annual estimates of snakebite-induced deaths for 138 countries were obtained from the data published
by Kasturiratne et al [4] and depicted on a world map using Epi-info; the darker a country’s colour the greater the estimated snakebite mortality – see
key for details.
doi:10.1371/journal.pntd.0000569.g001
Author Summary
Every year snake envenoming kills more people in the
tropics than some of the world’s recognised neglected
tropical diseases (NTDs), including schistosomiasis and
leishmaniasis. While lacking the epidemic potential of an
infectious/vector-borne disease, snake envenoming in
rural tropical communities has as great a medical mortality,
if not morbidity, as the NTDs. The recent categorisation of
snake envenoming as an NTD is an important advance that
hopefully will result in the wider recognition and allocation
of resources, particularly since death from snake enven-
oming is preventable; antivenom is very effective when
the appropriate antivenom is correctly administered.
Snake envenoming urgently requires international support
to instigate the epidemiological, health education, and
effective treatment initiatives that proved so potent in
addressing the medical burden of NTDs such as leprosy
and dracunculosis. All the global estimates of snake
envenoming and deaths from snakebite indicate that
mortality is highest in the world’s tropical countries. Here
we examined associations between the globally available
data on (i) snakebite-induced mortality and (ii) socioeco-
nomic markers of poverty. Our data unequivocally
establishes that snake envenoming is globally associated
with poverty, a distinctive characteristic of the neglected
tropical diseases.
Snakebite and Poverty
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that figures for ‘The Percentage of the Labour Force in
Agriculture’ are strongly correlated with global snakebite mortality
(Figure 2c). The survival of many of the rural poor is dependent
upon their non-mechanised, low-cost farming techniques and it is
a cruel irony that it is exactly these practices that place them at
such high risk of snakebite, and that their feet, legs and hands are
the most frequent anatomical sites of snakebite in Africa [25,26],
Asia [27,28] and Latin America [29]. The tissue necrotic effects of
snake envenoming are thought to afflict many more survivors of
snakebite than victims who succumb [30]. Detailed community-
based DALY/QALY-type assessments of the true burden imposed
by the tissue destructive effects of snake envenoming on these
communities are urgently required. There are very few reports in
the literature examining the socioeconomic impact of snakebite
[31–33] and none that we could find concerning the long-term
psychological effects of snakebite. It is important that these types of
studies are undertaken and the results appropriately disseminated
to ensure that governmental, non-governmental and international
health agencies understand the medical and sociological conse-
quences of snakebite and the implication for the strategic
allocation of scarce health resources.
As with some other NTDs, effective therapy for snake
envenoming is available. Antivenom is immunoglobulin purified
from the blood of venom-immunised horses and sheep (and rarely
other animals). While conceptually simple, the manufacturing
process requires GMP-standard production plants and is reliant
upon the husbandry and handling of both horses and venomous
snakes. Antivenom is therefore relatively expensive (eg, US$100/
vial in S Africa) compared to many other medications used in the
tropics. Presumably for this reason, in much of Latin America
antivenom manufacture is government-subsidised and antivenom
is usually provided free to the patient. This provision and delivery
of effective therapy to the at-risk communities may be an
important factor in explaining why although snakebite incidence
in Latin America is high (129,000), the mortality rates are low
(1.78%; 2,300 deaths). Much of Latin America has a high Human
Development Index (Figure S1). In contrast, Sub-Saharan African
countries, where snakebite victims are charged commercial rates
for antivenom (when available), are at the opposite end of the HDI
scale. The strong correlation between global ‘Per Capita
Government Expenditure on Health’ and snakebite mortality
(Figure 2b), illustrates the tragedy that the countries with the
highest burden of snakebite mortality are those with the most
limited ability to purchase effective antivenom.
There are clearly limitations to this kind of analysis: much of the
mortality data is estimated and the indicators, although standard,
are still only relatively crude indicators. The limitations are
indicated by the anomaly of India, with the highest global
Figure 2. Snakebite mortality and poverty. The annual estimates of snakebite mortality (log scale) for 138 countries were plotted against annual
estimates, where available, of a) Human Development Index (high - blue dots; medium - red dots; low - green dots), b) Per Capita Government
Expenditure on Health (US$; log scale), c) Percentage Labour Force in Agriculture (%) and d) Gross Domestic Product (US$; log scale).
doi:10.1371/journal.pntd.0000569.g002
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snakebite mortality rate but medium Human Development
(Supplementary Figure 1) and Human Poverty [11] indices. This
is likely to reflect factors such as the huge variation of income
within India and might also be explained by complex consider-
ations of population and venomous snake densities, antivenom
effectiveness and clinical practices and guidelines [34]. Neverthe-
less, with only occasional exceptions, our approach is robust in
demonstrating the relationship of snakebite to socioeconomic
markers of poverty.
The clinical effectiveness of most antivenoms means that
snakebite is, in WHO parlance, a ‘tool-ready NTD disease’. This
is encouraging: unlike some NTDS, the principles of producing a
therapy against snakebite are established, albeit with scope for
considerable improvement. As detailed in the WHO Global
Plan to Combat NTDs [8], what is required now to resolve
the problems of snake bite is a coordinated effort to (i) assess
the medical burden (to determine the scale and location of the
therapeutic need), (ii) where possible, to integrate snakebite
Figure 3. Snakebite and agriculture in rural North-East Nigeria.
doi:10.1371/journal.pntd.0000569.g003
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initiatives with those currently pursued for other NTDs, (iii)
strengthen health care systems by appropriate capacity building
initiatives, (iv) develop communication systems to disseminate
‘disease burden’ information to improve advocacy/public aware-
ness, (v) improve access to affordable, effective treatment and (vi)
establish a framework of implementation and evaluation. The
scale of this undertaking is daunting but the recent recognition by
the WHO that snakebite is a NTD [9] and the establishment of
the Global Snakebite Initiative [7] by the International Society of
Toxinology is evidence that that the process has already started
and that there is enthusiasm for the task.
One of the major hurdles will be to ensure the affordability and
effectiveness of antivenom. For most NTDs, once the effectiveness
of a treatment has been established, it can be utilised worldwide -
which improves commercial economies of scale and encourages
widespread pharmaceutical support and drug donation [8]. In
contrast, the clinical and geographic effectiveness of antivenom is
restricted to the species of snake whose venom was used in its
manufacture. This severely limits the implementation of econo-
mies of scale and, by inference, the commercial incentives for the
involvement of ‘large pharma’. In some regions such as sub-
Saharan Africa, until very recently there was only one source of
effective antivenom and a crisis in antivenom supply to the
continent [35,36]. Reports of this ‘therapeutic vacuum’ attracted
the commercial influx of ineffective antivenoms manufactured
from venoms from non-African snakes [37–41].
Therefore, despite the effectiveness of current antivenoms, there
are compelling reasons to encourage research to broaden the
geographic efficacy and improve the commercial viability of
antivenom therapy. There are encouraging experimental devel-
opments in this area, including ‘antivenomics’ [42] and ‘epitope-
string immunogen’ [43,44] approaches, whose objectives are to
maximise the clinical and snake-species efficacy of snakebite
serotherapy and minimise manufacturing costs. There are an
estimated 20–94,000 snakebite deaths annually, predominantly
occurring in the rural poor in the tropics. Improved antivenoms,
implementation of the WHO-recommended strategies and above
all, international recognition of the importance of the problem
could help to reduce many of these deaths.
Supporting Information
Figure S1 Human Development Index.
Found at: doi:10.1371/journal.pntd.0000569.s001 (1.02 MB EPS)
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